ARCT Valuation

Arcturus Therapeutics Holdings Inc

Add to Watchlist

Advanced Chart

17.480

+0.12(0.691%)1D

Overview
Forecast
Valuation
Earnings

ARCT Relative Valuation

ARCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARCT is overvalued; if below, it's undervalued.

Historical Valuation

Arcturus Therapeutics Holdings Inc (ARCT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5.64 is considered Overvalued compared with the five-year average of -9.71. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 7.92 to 13.88 according to relative valuation methord. Compared to the current price of 17.48 USD , Arcturus Therapeutics Holdings Inc is Overvalued By 25.92%.

Relative Value

Fair Zone

7.92-13.88

Current Price：17.48

25.92%

Overvalued

-5.92

Trailing

Forward

-3.20

EV/EBITDA

Arcturus Therapeutics Holdings Inc. (ARCT) has a current EV/EBITDA of -3.20. The 5-year average EV/EBITDA is -2.14. The thresholds are as follows: Strongly Undervalued below -8.87, Undervalued between -8.87 and -5.50, Fairly Valued between 1.22 and -5.50, Overvalued between 1.22 and 4.58, and Strongly Overvalued above 4.58. The current Forward EV/EBITDA of -3.20 falls within the Historic Trend Line -Fairly Valued range.

-3.41

EV/EBIT

Arcturus Therapeutics Holdings Inc. (ARCT) has a current EV/EBIT of -3.41. The 5-year average EV/EBIT is -13.23. The thresholds are as follows: Strongly Undervalued below -92.77, Undervalued between -92.77 and -53.00, Fairly Valued between 26.53 and -53.00, Overvalued between 26.53 and 66.30, and Strongly Overvalued above 66.30. The current Forward EV/EBIT of -3.41 falls within the Historic Trend Line -Fairly Valued range.

5.64

Arcturus Therapeutics Holdings Inc. (ARCT) has a current PS of 5.64. The 5-year average PS is 13.57. The thresholds are as follows: Strongly Undervalued below -36.92, Undervalued between -36.92 and -11.68, Fairly Valued between 38.81 and -11.68, Overvalued between 38.81 and 64.06, and Strongly Overvalued above 64.06. The current Forward PS of 5.64 falls within the Historic Trend Line -Fairly Valued range.

-3.40

P/OCF

Arcturus Therapeutics Holdings Inc. (ARCT) has a current P/OCF of -3.40. The 5-year average P/OCF is -0.48. The thresholds are as follows: Strongly Undervalued below -43.25, Undervalued between -43.25 and -21.86, Fairly Valued between 20.91 and -21.86, Overvalued between 20.91 and 42.30, and Strongly Overvalued above 42.30. The current Forward P/OCF of -3.40 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Arcturus Therapeutics Holdings Inc. (ARCT) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.73. The thresholds are as follows: Strongly Undervalued below -33.13, Undervalued between -33.13 and -17.93, Fairly Valued between 12.47 and -17.93, Overvalued between 12.47 and 27.67, and Strongly Overvalued above 27.67. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Arcturus Therapeutics Holdings Inc (ARCT) has a current Price-to-Book (P/B) ratio of 2.04. Compared to its 3-year average P/B ratio of 2.34 , the current P/B ratio is approximately -12.77% higher. Relative to its 5-year average P/B ratio of 3.03, the current P/B ratio is about -32.78% higher. Arcturus Therapeutics Holdings Inc (ARCT) has a Forward Free Cash Flow (FCF) yield of approximately -14.11%. Compared to its 3-year average FCF yield of -6.78%, the current FCF yield is approximately 108.00% lower. Relative to its 5-year average FCF yield of -9.24% , the current FCF yield is about 52.73% lower.

2.04

P/B

Median3y

2.34

Median5y

3.03

-14.11

FCF Yield

Median3y

-6.78

Median5y

-9.24

Competitors Valuation Multiple

The average P/S ratio for ARCT's competitors is 4.19, providing a benchmark for relative valuation. Arcturus Therapeutics Holdings Inc Corp (ARCT) exhibits a P/S ratio of 5.64, which is 34.43% above the industry average. Given its robust revenue growth of -43.24%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARCT.O

Arcturus Therapeutics Holdings Inc

Zevra Therapeutics Inc

Compass Therapeutics Inc.

Loss

-100.00%

480.40M

Performance Decomposition

Market capitalization of ARCT decreased by 17.16% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.91 to -7.81.

The secondary factor is the Margin Expansion, contributed -6.05%to the performance.

Overall, the performance of ARCT in the past 1 year is driven by P/E Change. Which is more unsustainable.

-43.24%

49.86M → 28.30M

Revenue Growth

-6.05%

-34.53 → -32.44

Margin Expansion

32.13%

-5.91 → -7.81

P/E Change

-17.16%